ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis

International Journal of Gynecological Cancer 2026

View at publisher
Authors: A. Clamp, Iain McNeish, Domenico Radice, Rosemary Lord, Agnieszka Michael, Audrey Cook, Roshan Agarwal, Axel Walther, Sarah Patricia Blagden, Dearbhaile O'Donnell, James D. Brenton, Sudha Sundar
+7 more Cristiana Sessa, Laura Murphy, Francesca Schiavone, Aleksandra Gentry-Maharaj, Richard Kaplan, Mahesh Kb Parmar, Jonathan A. Ledermann
DOI: 10.1016/j.ijgc.2025.102893
Cited by: 1

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment HER2/EGFR in Cancer Research PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
102893–102893
Publication date
1 February 2026
Language
EN